Literature DB >> 15681856

Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Yuri E Nikiforov1.   

Abstract

Recent molecular studies have provided new insights into thyroid carcinogenesis. In thyroid papillary carcinomas at least three initiating events may occur, which are point mutations in the BRAF and RAS genes and RET/PTC rearrangements. Tumors harboring mutant BRAF and RAS are prone to progression to poorly differentiated and anaplastic carcinoma, but most likely require additional mutations to trigger this process. In thyroid follicular carcinomas, two known initiating events are RAS mutations and PAX8-PPARgamma rearrangements, and RAS predisposes to dedifferentiation of follicular carcinomas. p53 and beta-catenin mutations, found with increasing incidence in poorly differentiated and anaplastic carcinomas but not in well-differentiated tumors, may serve as a direct molecular trigger of tumor dedifferentiation. Additional evidence for progression from a preexisting well-differentiated carcinoma to poorly differentiated and anaplastic carcinoma comes from the studies of loss of heterozygosity and comparative genomic hybridization. Molecular studies, although limited by the lack of uniform histologic criteria for poorly differentiated carcinomas, revealed no genetic mutations or chromosomal abnormalities that are unique for poorly differentiated carcinoma and not present in well-differentiated or anaplastic carcinomas. This suggests that poorly differentiated carcinoma, as a group, represents a distinct step in the evolution from well-differentiated to anaplastic thyroid carcinoma, rather than an entirely separate type of thyroid malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681856     DOI: 10.1385/ep:15:4:319

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  64 in total

1.  Absence of mutations in the beta-catenin and adenomatous polyposis coli genes in papillary and follicular thyroid carcinomas.

Authors:  N Miyake; H Maeta; S Horie; Y Kitamura; E Nanba; K Kobayashi; T Terada
Journal:  Pathol Int       Date:  2001-09       Impact factor: 2.534

2.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.

Authors:  D J Powell; J P Russell; G Li; B A Kuo; V Fidanza; K Huebner; J L Rothstein
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

4.  PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses.

Authors:  Marina N Nikiforova; Paul W Biddinger; Christy M Caudill; Todd G Kroll; Yuri E Nikiforov
Journal:  Am J Surg Pathol       Date:  2002-08       Impact factor: 6.394

5.  BRAF mutations in papillary carcinomas of the thyroid.

Authors:  Toshihiko Fukushima; Shinichi Suzuki; Miyuki Mashiko; Tohru Ohtake; Yoshiyuki Endo; Yuji Takebayashi; Koji Sekikawa; Koichi Hagiwara; Seiichi Takenoshita
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

6.  E-cadherin loss rather than beta-catenin alterations is a common feature of poorly differentiated thyroid carcinomas.

Authors:  A S Rocha; P Soares; E Fonseca; J Cameselle-Teijeiro; M C Oliveira; M Sobrinho-Simões
Journal:  Histopathology       Date:  2003-06       Impact factor: 5.087

7.  Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

Authors:  R Donghi; A Longoni; S Pilotti; P Michieli; G Della Porta; M A Pierotti
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 8.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  p53 gene mutation in thyroid carcinoma.

Authors:  Y S Ho; S C Tseng; T Y Chin; L L Hsieh; J D Lin
Journal:  Cancer Lett       Date:  1996-05-15       Impact factor: 8.679

10.  p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas.

Authors:  T Nakamura; I Yana; T Kobayashi; E Shin; K Karakawa; S Fujita; A Miya; T Mori; I Nishisho; S Takai
Journal:  Jpn J Cancer Res       Date:  1992-12
View more
  56 in total

Review 1.  How to define follicular thyroid carcinoma?

Authors:  Kurt Werner Schmid; Nadir Rashad Farid
Journal:  Virchows Arch       Date:  2006-02-28       Impact factor: 4.064

Review 2.  An evidence-based review of poorly differentiated thyroid cancer.

Authors:  Enoch M Sanders; Virginia A LiVolsi; James Brierley; Jennifer Shin; Gregory W Randolph
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

3.  Identifying genetic alterations in poorly differentiated thyroid cancer: a rewarding pursuit.

Authors:  Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2009-12       Impact factor: 5.958

Review 4.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

Review 5.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

Review 6.  Lessons from mouse models of thyroid cancer.

Authors:  Caroline S Kim; Xuguang Zhu
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

7.  Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels.

Authors:  H-U G Weier; J Kwan; C-M Lu; Y Ito; M Wang; A Baumgartner; S W Hayward; J F Weier; H F Zitzelsberger
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

Review 8.  Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.

Authors:  Robert C Smallridge; Laura A Marlow; John A Copland
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

9.  Genetic Predisposition to Familial Nonmedullary Thyroid Cancer: An Update of Molecular Findings and State-of-the-Art Studies.

Authors:  Elena Bonora; Giovanni Tallini; Giovanni Romeo
Journal:  J Oncol       Date:  2010-06-10       Impact factor: 4.375

10.  PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Authors:  Matthew W Rosenbaum; Benjamin J Gigliotti; Sara I Pai; Sareh Parangi; Heather Wachtel; Mari Mino-Kenudson; Viswanath Gunda; William C Faquin
Journal:  Endocr Pathol       Date:  2018-03       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.